-
A
Identification of dsRNAs activated by TERT‐WT or TERT‐K626A using dsRIP‐seq in U2OS cells. AluYb9 and tRNA‐Thr‐ACG as positive and negative controls, respectively.
-
B
Quantification of antisense/sense transcripts of ERVs activated by TERT‐WT or TERT‐K626A in U2OS and HeLa cells using strand‐specific RT–qPCR.
-
C
Regression analysis of the correlation between TERT and TA‐ERVs expression in 103 tumour samples across 11 cancer types. BRCA (breast invasive carcinoma), n = 17. cHL (classical Hodgkin lymphoma), n = 5. COADREAD (colon adenocarcinoma/rectum adenocarcinoma), n = 6. HGSC (high‐grade serous ovarian cancer), n = 6. KIRC (kidney renal clear cell carcinoma), n = 12. LIHC (liver hepatocellular carcinoma), n = 9. LUAD (lung adenocarcinoma), n = 6. OSCC (oral squamous cell carcinoma), n = 8. PAAD (pancreatic adenocarcinoma), n = 10. PRAD (prostate adenocarcinoma), n = 6. THCA (thyroid carcinoma), n = 18.
-
D
MeDIP‐qPCR analysis of TA‐ERVs sites in HeLa cells ectopically expressing TERT‐WT or TERT‐K626A. Primer sets recognizing exon 8 of the human ZC3H13 gene and a gene desert on chromosome 12 were used for positive and negative controls, respectively.
-
E
ChIP‐qPCR for TERT and Sp1 targets on TA‐ERVs in U2OS cells with TERT ectopic expression and in HeLa cells. β‐actin promoter was used as a negative control, and VEGF promoter was used as a positive control.